losartan has been researched along with Fatigue in 5 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan (Los) was intracerebroventricularly injected in rats before running until fatigue (n = 6 per group)." | 7.76 | Central fatigue induced by losartan involves brain serotonin and dopamine content. ( Coimbra, CC; Leite, LH; Marubayashi, U; Rodrigues, AG; Soares, DD, 2010) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 6.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "Losartan (Los) was intracerebroventricularly injected in rats before running until fatigue (n = 6 per group)." | 3.76 | Central fatigue induced by losartan involves brain serotonin and dopamine content. ( Coimbra, CC; Leite, LH; Marubayashi, U; Rodrigues, AG; Soares, DD, 2010) |
| " When fluconazole, a potent inhibitor of CYP2C9, was added to the treatment regimen, the patient developed ataxia, tremor, fatigue, slurred speech and somnolence, indicating phenytoin intoxication." | 3.76 | Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. ( Bergman, U; Bertilsson, L; Engström Hellgren, K; Helldén, A; Masquelier, M; Nilsson Remahl, I; Odar-Cederlöf, I; Ramsjö, M, 2010) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 2.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "1%) were the most commonly reported clinical adverse experiences in patients treated with losartan." | 2.39 | Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marshall, M | 1 |
| Goldberg, AI | 2 |
| Dunlay, MC | 2 |
| Sweet, CS | 2 |
| Leite, LH | 1 |
| Rodrigues, AG | 1 |
| Soares, DD | 1 |
| Marubayashi, U | 1 |
| Coimbra, CC | 1 |
| Helldén, A | 1 |
| Bergman, U | 1 |
| Engström Hellgren, K | 1 |
| Masquelier, M | 1 |
| Nilsson Remahl, I | 1 |
| Odar-Cederlöf, I | 1 |
| Ramsjö, M | 1 |
| Bertilsson, L | 1 |
1 review available for losartan and Fatigue
| Article | Year |
|---|---|
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 1995 |
1 trial available for losartan and Fatigue
| Article | Year |
|---|---|
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 1995 |
3 other studies available for losartan and Fatigue
| Article | Year |
|---|---|
COVID and the brain: researchers zero in on how damage occurs.
Topics: Animals; Antibodies, Viral; Astrocytes; Autoantibodies; Autopsy; Brain; Capillaries; COVID-19; Crice | 2021 |
Central fatigue induced by losartan involves brain serotonin and dopamine content.
Topics: 3,4-Dihydroxyphenylacetic Acid; Angiotensin II Type 1 Receptor Blockers; Animals; Body Temperature; | 2010 |
Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9.
Topics: Alleles; Angiotensin II Type 1 Receptor Blockers; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; At | 2010 |